Document:

Exhibit 10.33

 

 

 

BOINGO WIRELESS, INC.
  10960 WILSHIRE BLVD., SUITE 800 
 LOS ANGELES, CA 90024

 

February 21, 2019

 

 

Mike Finley

 

Dear Mike:

 

Boingo Wireless, Inc. (the “Company”) is pleased to offer you employment on the terms set forth in this letter agreement (the “Agreement”).

 

1.                                    Position.  Commencing on or about March 18, 2019 (your “Start Date”), you will become an executive officer of the Company, your title and position will be Chief Executive Officer, reporting to the Board of Directors (the “Board”).  This is a full-time position and your place of employment will be our headquarters in Los Angeles.  While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company.  During your time as Chief Executive Officer, you will continue to serve on the Board, however, effective as of your Start Date you will no longer serve on any Board committees.  Subject to the written advance approval from the Chairman of the Board (which approval will not be unreasonably withheld), you may serve on the boards of directors of other entities, provided that such activity does not violate any Company policy, create a conflict of interest with the Company or otherwise interfere with your ability to perform your responsibilities hereunder. By signing this Agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company in your new role.

 

2.                                    Cash Compensation.  The Company will pay you an annual base salary at the rate of $500,000 per year, payable in accordance with the Company’s standard payroll schedule.  This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time.  In addition, you will be eligible to be considered for a cash-incentive bonus for each fiscal year of the Company.  The bonus (if any) will be awarded based on objective or subjective criteria established and approved by the Compensation Committee.  Your target bonus will be equal to 100% of your annual base salary, measured as of the last day of each fiscal year.  Any bonus for a fiscal year will be paid within 21⁄2 months after the close of that fiscal year, but only if you are still employed by the Company at the time of payment.  The determinations of the Compensation Committee with respect to your bonus will be final and binding.

 

In addition, within 30 days of your Start Date, the Company will pay you a bonus of $300,000, subject to applicable withholdings.  If before the second anniversary of your Start Date you terminate your employment with the Company other than as a result of (I) an Involuntary Termination (as defined below) or (II) your death or disability, then you will be required to

 

 

February 21, 2019

Page 2

 

 

reimburse the Company a portion of this bonus, pro-rated based upon the number of complete months you have been employed since your Start Date divided by 24.

 

3.                                    Employee Benefits.

 

(a)                               As a regular employee of the Company, you will be eligible to participate in the Company’s standard employee and executive benefits programs, as such are in effect from time to time.  In addition, under current Company policy, as an executive officer the paid time-off to which you are entitled is unlimited and does not accrue to the extent unused.  The Company will reimburse you for your business expenses subject to its corporate expense reimbursement policy.

 

(b)                              Relocation.  Although you will travel for Company business from time to time, your primary workplace will be at our headquarters in Los Angeles where we will need you to be physically present on a substantially full-time basis.  To facilitate this geographic transition for you, the Company offers you the following benefits, taxable to you as required by applicable law:

 

(i)                                                                                                                         A temporary housing allowance for the first 18 months of your employment of up to an aggregate of $180,000 (the “Housing Allowance”), payable with respect to your securing temporary housing for yourself and your family in proximity to the Company’s headquarters, which will paid to you upon your submission of receipts for your temporary housing expenses as well as reasonable commuting expenses for you and your spouse during that period; and

 

(ii)                                                                                                                     A relocation allowance (the “Relocation Allowance”) of up to $400,000 (inclusive of any amount paid to you as Housing Allowance), which amount is available to reimburse you for expenses related to relocating your family and household from San Diego to Los Angeles including substantiated expenses such as moving expenses for household goods, storage fees, realtor fees, financing and mortgage closing costs and other reasonable expenses typically incurred in connection with relocating to a new geography.  For the sake of clarity, the Relocation Allowance (1) shall not cover loss of value on home sale, (2) shall not be used to cover the actual cost of a new home, and (3) unless otherwise extended by the Board or its Compensation Committee, shall be available to you for a relocation completed within the first two years of your Start Date.

 

If before the second anniversary of your Start Date you terminate your employment with the Company other than as a result of (I) an Involuntary Termination or (II) your death or disability, then you will be required to reimburse the Company the aggregate amount of the Relocation Allowance (including any portion of such allowance that is the Housing Allowance) that has been paid to you, pro-rated based upon the number of complete months you have been employed since your Start Date divided by 24.

 

4.                                    Equity Grants.  Subject to the approval of the Board or its Compensation Committee, you will be granted two equity compensation awards in connection with your being hired as Chief Executive Officer.  Each equity award will be for restricted stock units (each, an

 

 

February 21, 2019

Page 3

 

 

“RSU  Grant”) over a number of shares of the Company’s Common Stock with a grant date aggregate value (per the Company’s standard award grant methodology) equal to $1,000,000 and each will have a three-year vesting term.   The first RSU Grant (the “Time-Based RSU Grant”) will be subject to annual service vesting based upon your continuous service as Chief Executive Officer.  The second RSU Grant (the “PRSU”) will be subject to vesting upon achievement of certain performance milestones applied to the PRSU grants made to the Company’s other executive officers in fiscal year 2019.

 

5.                                    Payments Upon Termination.  If your employment with the Company terminates other than as set forth in Section 6 below, then (a) all vesting will cease immediately with respect to your then-outstanding RSU Grants (and other equity awards), and (b) the only amounts payable to you by the Company will be any unpaid base salary due for periods prior to the date of termination of your employment plus any as-yet unpaid benefits that were vested and nonforfeitable prior to termination.  Such payment, if any, will be made promptly upon termination and within the period of time mandated by law.  If your employment terminates for any reason other than those specified in Section 6 below, the payment described in this Section 5 will be the only payment to which you are entitled in connection with your termination.

 

6.                                    Severance Benefits.

 

(a)                               General.  If you are subject to an Involuntary Termination, then you will be entitled to the benefits described in this Section 6.  However, you will not be entitled to any of the benefits described in this Section 6 unless you have (i) returned all Company property in your possession, (ii) resigned as a member of the Board and of the boards of directors of all of the Company’s subsidiaries, to the extent applicable, and (iii) executed a general release of all claims that you may have against the Company or persons affiliated with the Company, in the form provided to you by the Company at the time of your termination, substantially in the form attached as Schedule I (the “Release”).  You must execute and return the release on or before the date specified by the Company in the Release (the “Release Deadline”).  The Release Deadline will in no event be later than fifty (50) days after your Separation.  If you fail to return the Release on or before the Release Deadline, or if you revoke the Release, then you will not be entitled to the benefits described in this Section 6.

 

Notwithstanding the foregoing, the Company may immediately discontinue all benefits or revoke any vesting acceleration described in this Section 6 (in addition to pursuing all other legal and equitable remedies) if you breach the Confidentiality Agreement (as defined below) that you will be required to sign in connection with your employment or any other material agreement with the Company that by its terms continues in force following your Separation.

 

(b)                              Termination Not in Connection With Change in Control.  Subject to the requirements set forth in Section 6(a) above, if you experience an Involuntary Termination before the earlier of three (3) months before or more than eighteen (18) months after a Change in Control, then you will be entitled to the following:

 

 

February 21, 2019

Page 4

 

 

(i)                                  Cash Severance.  The Company will pay you on a quarterly basis cash severance (the “Cash Severance”) in an aggregate amount equal to the sum of (A)  your base salary as in effect at the time of your Separation for a period beginning on the day after your Separation and ending on the date eighteen (18) months after your Separation, and (B) an amount equal to 150% of your target annual incentive bonus for the year of your Separation. Subject to the Company’s having first received an effective Release pursuant to Section 6(a) above, the salary continuation payments will commence within sixty (60) days after your Separation and, once they commence, will include any unpaid amounts accrued from the date of your Separation.  However, if the sixty (60)-day period described in the preceding sentence spans two calendar years, then the payments will in any event begin in the second calendar year.

 

(ii)                              Pro-Rated Bonus.  The Company will pay you a lump sum cash amount equal to the pro-rated portion of your annual incentive bonus (the “Pro-Rated Bonus”) for the year of your Separation, based upon achievement of applicable performance objectives as determined by the Board or its Compensation Committee on the same schedule and same basis as paid to other Company executives.  Subject to the Company’s having first received an effective Release pursuant to Section 6(a) above, such payment will be made within seventy-five (75 days after the end of the year of your Separation.  For the sake of clarity, the pro-ration calculation will be done on a daily basis for the portion of the year during which your employment continued prior to the Separation date.

 

(iii)                          Additional Payment in Lieu of Health Benefit.  The Company will cover your cost of medical benefits continuation coverage (the “COBRA Benefits”) for you and your eligible dependents with respect to the Company’s health insurance plans in which you and your dependents were participating as of your Separation for a period ending on the earlier of (A) eighteen (18) months following your Separation or (B) the date on which you become eligible for medical benefits coverage provided by another employer.  This amount will be made on a tax-free basis, if permitted under applicable law in the Company’s sole determination, or on a taxable basis to you if not so permitted.

 

(iv)                          Equity Acceleration.  You will receive (A) twenty four (24) months of additional vesting credit under the service-based vesting conditions applicable to your then-outstanding Time-Based RSU Grants, and (B) pro-rata monthly vesting credit for the period of your continuous service plus an additional twenty-four (24) months with respect to the service-based vesting conditions applicable to your then-outstanding PRSUs (in accordance with the Company’s standard PRSU award agreement); provided, however, that in the event acceleration of the settlement date of an RSU Grant would result in additional taxes and penalties under Section 409A of the Code, then the vesting of such award shall accelerate but settlement of the RSU Grant shares (or cash, if applicable) shall occur on the date(s) specified in the agreement governing the RSU Grant.

 

(c)       Termination in Connection With Change in Control.  Subject to the requirements set forth in Section 6(a) above, if you experience an Involuntary Termination

 

 

February 21, 2019

Page 5

 

 

within three (3) months prior to or eighteen (18) months following a Change in Control, then you will be entitled to the Cash Severance, the Pro-Rated Bonus and the COBRA Benefits on the same terms and conditions as described above plus you will receive full vesting credit under the service-based  vesting conditions applicable to your then-outstanding Time-Based RSU Grants and PRSUs (in accordance with the Company’s standard PRSU award agreement); provided, however, that in the event acceleration of the settlement date of an RSU Grant would result in additional taxes and penalties under Section 409A of the Code, then the vesting of such award shall accelerate but settlement of the RSU Grant shares (or cash, if applicable) shall occur on the date(s) specified in the agreement governing the RSU Grant.

 

7.                                    Limitation on Payments.

 

(a)                               Scope of Limitation.  This Section 7 will apply only if the accounting firm serving as the Company’s independent public accountants immediately prior to a Change in Control (the “Accounting Firm”) determines that the after-tax value of all Payments (as defined below) to you under Section 6 of this Agreement, taking into account the effect of all federal, state and local income taxes, employment taxes and excise taxes applicable to you (including the excise tax under Section 4999 of the Code), will be greater after the application of this Section 7 than it was before the application of this Section 7.  If this Section 7 applies, it will supersede any contrary provision of this Agreement.  For purposes of this Section 7, the term “Company” will also include affiliated corporations to the extent determined by the Accounting Firm in accordance with Section 280G(d)(5) of the Code.

 

(b)                              Basic Rule.  In the event that the Accounting Firm determines that any payment or transfer by the Company to or for your benefit (a “Payment”) would be nondeductible by the Company for federal income tax purposes because of the provisions concerning “excess parachute payments” in Section 280G of the Code and pursuant to the regulations thereunder, then provided that Subsection (a) results in applicable of this Section 7, the aggregate present value of all Payments will be reduced (but not below zero) to the Reduced Amount.  For purposes of this Section 7, the “Reduced Amount” will be the amount, expressed as a present value, which maximizes the aggregate present value of the Payments without causing any Payment to be nondeductible by the Company because of Section 280G of the Code.

 

(c)                               Reduction of Payments.  If the Accounting Firm determines that any Payment would be nondeductible by the Company because of Section 280G of the Code, and if none of the Payments is subject to Section 409A of the Code, then the reduction will occur in the manner you elect in writing prior to the date of payment; provided, however, that if the manner elected by you pursuant to this sentence could in the opinion of the Company result in any of the Payments becoming subject to Section 409A of the Code, then the following sentence will instead apply.  If any Payment is subject to Section 409A of the Code, or if you fail to elect an order under the preceding sentence, then the reduction will occur in the following order:  (i) cancellation of acceleration of vesting of any equity awards for which the exercise price (if any) exceeds the then-fair market value of the underlying Company Common Stock, (ii) reduction of cash payments (with such reduction being applied to the payments in the reverse order in which they would otherwise be made (that is, later payments will be reduced before earlier payments)), and (iii) cancellation of acceleration of vesting of equity awards not covered under (i) above;

 

 

February 21, 2019

Page 6

 

 

provided, however, that in the event that acceleration of vesting of equity awards is to be cancelled, such acceleration of vesting will be cancelled in the reverse order of the date of grant of such equity awards (that is, later equity awards will be canceled before earlier awards).

 

(d)                             Fees of Accounting Firm and Required Data.  The Company will pay all fees, expenses and other costs associated with retaining the Accounting Firm for the purposes described in this Section 7.  You and the Company will provide to the Accounting Firm all data in the Company’s possession or under its control that the Accounting Firm reasonably requires for the purposes described in this Section 7.

 

8.                                    Further Obligations to the Company.

 

(a)                               General.  You acknowledge your obligations under, and agree to comply with, all applicable laws and all Company policies in effect at all times and from time to time during your employment with the Company.  You further acknowledge and agree that such applicable laws or policies may relate to the general terms of your employment with the Company or to a specific component of your compensation. By way of example, such applicable laws or policies may include any Company recoupment or clawback policy, insider trading policy or code(s) of conduct or other policies adopted under, pursuant to or in light of, or requirements imposed by, the Sarbanes-Oxley Act of 2002 or the Dodd-Frank Wall Street Reform and Consumer Protection Act.

 

(b)                              Confidential Information.  Like all Company employees, you will be required, as a condition of your employment, to sign the Employee Inventions and Confidentiality Agreement and Mutual Agreement to Arbitrate Claims (the “Confidentiality Agreement”).

 

9.                                    Employment Relationship.  Employment with the Company is for no specific period of time.  Your employment with the Company remains “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause.  Any contrary representations that may have been made to you are superseded by this Agreement.  This is the full and complete agreement between you and the Company on this term.  Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).

 

10.                            Recoupment Policy.  The Company intends to adopt a clawback policy, as and when required by applicable law and/or stock exchange listing standards, governing the Company’s obligation to recoup from you incentive compensation paid or provided to you by the Company under specified events and circumstances including upon a restatement of Company financial statements.  The Company anticipates that this policy will apply to you while you continue to serve as Chief Executive Officer and for some period following termination of your position as an executive officer of the Company.  You acknowledge that it is a condition of your position as Chief Executive Officer that you be subject to the Company’s clawback policy as in effect from time to time.

 

 

February 21, 2019

Page 7

 

 

11.                            Tax Matters.

 

(a)                               All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.  You are encouraged to obtain your own tax advice regarding your compensation from the Company.  You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board related to tax liabilities arising from your compensation.

 

(b)                              Section 409A.  For purposes of Section 409A of the Code, each payment under Section 6 is hereby designated as a separate payment for purposes of Treasury Regulation 1.409A-2(b)(2).  If the Company determines that you are a “specified employee” under Section 409A(a)(2)(B)(i) of the Code at the time of your Separation, then (i) any payments under this Agreement, to the extent that they are not exempt from Section 409A of the Code (including by operation of the next following sentence) and otherwise subject to the taxes imposed under Section 409A(a)(1) of the Code (a “Deferred Payment”), will commence on the first business day following (A) the expiration of the six-month period measured from your Separation or (B) the date of your death and (ii) the installments that otherwise would have been paid prior to such date will be paid in a lump sum when such payments commence.  Notwithstanding the foregoing, any amount paid under this Agreement that either (1) satisfies the requirements of the “short-term deferral” rule set forth in Treasury Regulation 1.409A-1(b)(4); or (2) (A) qualifies as a payment made as a result of an involuntary separation from service pursuant to Treasury Regulation 1.409A-1(b)(9)(iii), and (B) does not exceed the Section 409A Limit will not constitute a Deferred Payment.  The provisions of this Agreement are intended to comply with, or be exempt from, the requirements of Section 409A of the Code so that none of the payments and benefits to be provided under this Agreement will be subject to the additional tax imposed under Section 409A of the Code, and any ambiguities herein will be interpreted to so comply or be exempt. You and the Company agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions as are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to you under Section 409A of the Code. In no event will the Company reimburse you for any taxes that may be imposed on you as result of Section 409A of the Code.

 

12.                            Interpretation, Amendment and Enforcement.  This Agreement constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes and replaces any prior agreements, representations or understandings (whether written, oral, implied or otherwise) between you and the Company.   This Agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company.  The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by California law, excluding laws relating to conflicts or choice of law.  For purposes of obtaining an injunction or to enforce the arbitration agreement you will sign, you and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in California, but

 

 

February 21, 2019

Page 8

 

 

shall arbitrate  any Dispute or any claim related to any Dispute in accordance with the arbitration agreement.  By signing this Agreement, you acknowledge and agree that you will no longer be eligible for any benefits or payments  except as otherwise expressly provided in this Agreement.

 

13.                            Successors and Assignment.

 

(a)                               Company’s Successors.  Any successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets will assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under this Agreement, the term “Company” shall include any such successor to the Company, or to the Company’s business and/or assets, that executes and delivers the assumption agreement described in this Section 13(a) or which becomes bound by the terms of this Agreement by operation of law.

 

(b)                              Employee’s Successors.  The terms of this Agreement and all of your rights hereunder will inure to the benefit of, and be enforceable by, your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.  All of your obligations under this Agreement are personal to you and may not be transferred or assigned by you at any time.

 

14.                            Definitions.  The following terms have the meaning set forth below wherever they are used in this Agreement:

 

“Cause” means the occurrence of any one or more of the following: (a) your conviction by, or entry of a plea of “guilty” or nolo contendere in, a court of competent jurisdiction for any crime which constitutes a felony in the jurisdiction involved, (b) your commission of an act of theft or fraud, whether prior or subsequent to the date hereof, upon the Company, (c) your gross negligence in the scope of your services to the Company, (d) your breach of a material provision of any written agreement between you and the Company, (e) your continuing failure to perform assigned duties after receiving written notification of such failure from the Board of Directors with thirty (30) days to cure, unless a request to cure would be futile or (f) your failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested your cooperation.

 

“Change in Control” means (a) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company’s then-outstanding voting securities; (b) the consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets; (c) the consummation of a merger or consolidation of the Company with or into any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) more than fifty percent (50%) of the total voting power represented

 

 

February 21, 2019

Page 9

 

 

by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; or (d) individuals who are members of the Board of Directors (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board of Directors over a period of 12 months; provided, however, that if the appointment or election (or nomination for election) of any new member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such  new member shall, for purposes of this Agreement, be considered as a member of the Incumbent Board.

 

A transaction will not constitute a Change in Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction.  In addition, if a Change in Control constitutes a payment event with respect to any RSU Grant which provides for a deferral of compensation and is subject to Section 409A of the Code, then notwithstanding anything to the contrary in this Agreement, the transaction with respect to such RSU Grant must also constitute a “change in control event” as defined in Treasury Regulation 1.409A-3(i)(5) to the extent required by Section 409A of the Code.

 

“Code” means the Internal Revenue Code of 1986, as amended.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Involuntary Termination” means either (a) your Termination Without Cause (other than due to your death or Permanent Disability) or (b) your Resignation for Good Reason.

 

“Permanent Disability” means your total and permanent disability as defined in Section 22(e)(3) of the Code.

 

“Resignation for Good Reason” means a Separation as a result of your resignation within 12 months after one of the following conditions has initially come into existence without your express written consent:

 

(a)                               A material reduction of your duties, authority and responsibilities, relative to your duties, authority and responsibilities as in effect immediately prior to such reduction, or the assignment to you of such reduced duties, authority and responsibilities;

 

(b)                              A reduction in your base salary in effect immediately prior to such reduction;

 

(c)                               A material reduction in the kind or level of employee benefits to which you were entitled immediately prior to such reduction, with the result that your overall benefits package is materially reduced;

 

(d)                             A relocation to a facility or a location more than thirty-five miles from your then-present location that increases your one-way commute; or

 

 

February 21, 2019

Page 10

 

 

(e)                               The Company’s breach of this Agreement, including its failure to obtain the assumption of this Agreement by any successor (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company’s business and/or assets.

 

A Resignation for Good Reason will not be deemed to have occurred unless you give the Company written notice of the condition within 90 days after the condition initially comes into existence and the Company fails to remedy the condition within 30 days after receiving your written notice.

 

“Section 409A Limit” means the lesser of two times: (i) your annualized compensation based upon the annual rate of pay paid to you during the taxable year preceding your taxable year in which your termination of employment occurs, as determined under, and with such adjustments as are set forth in, Treasury Regulation  1.409A-1(b)(9)(iii)(A)(1) and any guidance issued with respect thereto or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which your employment is terminated.

 

“Separation” means a “separation from service,” as defined in the regulations under Section 409A of the Code.

 

“Termination Without Cause” means a Separation as a result of a termination of your employment by the Company without Cause, provided you are willing and able to continue performing services within the meaning of Treasury Regulation 1.409A-1(n)(1).

 

* * * * *

 

 

February 21, 2019

Page 11

 

 

You may indicate your agreement with these terms and accept this offer by signing and dating the enclosed duplicate original of this Agreement and the Confidentiality Agreement and returning them to me.

 

	
 
    	
Very   truly yours,
    
	
 
    	
 
    
	
 
    	
BOINGO   WIRELESS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   David Hagan
    	
 
    
	
 
    	
 
    
	
 
    	
Title:   Chief Executive Officer
    

 

I have read and accept this employment offer:

 

	
/s/   Mike Finley
    	
 
    
	
Signature of   Mike Finley
    	
 
    

 

	
Dated:   
    	
2/21/2019
    	
 
    

 

 

Attachment

 

Exhibit A:                             Confidentiality Agreement

 

 

February 21, 2019

Page 12

 

 

SCHEDULE I

 

FORM OF RELEASE OF CLAIMSEX-10.1

 Exhibit 10.1 

COOPERATION AGREEMENT 

This Cooperation Agreement (this “Agreement”) is made and entered into as of March 1, 2019 by and among Autoliv, Inc., a
Delaware corporation (the “Company”) and Cevian Capital II GP Limited, a limited company incorporated under the laws of the Bailiwick of Jersey (“Investor”) (the Company and Investor, each a “Party”
to this Agreement, and collectively, the “Parties”). 
 RECITALS 

WHEREAS, as of the date hereof, Investor beneficially owns shares of common stock of the Company (the “Company Common Stock”)
totaling, in the aggregate, 8,376,924 shares (the “Shares”), or approximately nine and six-tenths percent (9.6%), of the Company Common Stock issued and outstanding on the date hereof; and

 WHEREAS, as of the date hereof, the Company and Investor have determined to come to an agreement with respect to the nomination for
election of Min Liu (the “Investor Director”) to the Board of Directors of the Company (the “Board”) and certain other matters, as provided in this Agreement. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree as follows: 

1.    Nomination of Director and Related Agreements. 

(a)    Nomination of Director. The Company shall take all necessary actions to nominate the Investor Director for
election to the Board by the stockholders at the Company’s 2019 annual meeting of stockholders (the “2019 Annual Meeting”). 

(i)    If at any time prior to the 2019 Annual Meeting Investor’s aggregate ownership of Company
Common Stock decreases to less than eight percent (8.0%) of the then-outstanding Company Common Stock (other than as the result of a share issuance or similar Company action that increases the number of outstanding shares of Company Common Stock
(other than ordinary course compensatory equity issuances to management), in which event the eight percent (8.0%) threshold shall be correspondingly reduced to give effect to such share issuance), then this Agreement shall be null and void ab initio
and there shall be no obligation on the Company to nominate the Investor Director for election to the Board. 

(ii)    If the Investor Director is unable or unwilling to serve as a director for any reason, resigns as a
director or is removed as a director prior to the expiration of the Standstill Period (as defined herein), and at such time Investor has aggregate ownership of at least eight percent (8.0%) of the then-outstanding Company Common Stock (the
“Minimum Ownership Threshold”) (other than as the result of a share issuance or similar Company action that increases the number of outstanding shares of Company Common Stock (other than ordinary course compensatory equity issuances
to management), in which event the Minimum Ownership Threshold shall be correspondingly reduced to give effect to such share issuance), Investor shall have the ability to recommend a substitute director in accordance with this Section 1(a)(ii)
(any such replacement nominee shall be referred to as the “Investor Replacement Director”). Any Investor Replacement Director recommended by Investor shall be required to (i) qualify as “independent” pursuant to the
U.S. Securities and Exchange Commission (the “SEC”) and the listing standards of any exchange on which the securities of the Company are listed and (ii) satisfy the guidelines and policies with respect to service on the Board
applicable to all non-management directors. The Board, 

 
after taking into account the relevant financial and business experience of the proposed Investor Replacement Director, shall promptly (and in no case later than ten (10) business days) make
the determination whether the Investor Replacement Director is approved to be appointed to the Board, in each case, as reasonably determined by the Board. In the event the Board does not nominate such Investor Replacement Director for election at
the 2019 Annual Meeting, or after the 2019 Annual Meeting, appoint such Investor Replacement Director to the Board, Investor shall have the right to recommend additional substitute person(s) until an Investor Replacement Director stands for election
at the 2019 Annual Meeting, or after the 2019 Annual Meeting, is appointed to the Board, subject to this Section 1(a)(ii). Any Investor Replacement Director appointed to the Board in accordance with this Section 1(a)(ii) will be legally
bound by the terms and conditions applicable to the Investor Director under this Agreement. Following the appointment of any Investor Replacement Director to replace the Investor Director in accordance with this Section 1(a)(ii), any reference
to the Investor Director herein shall be deemed to include such replacement director. If at any time Investor’s aggregate beneficial ownership (as determined under Rule 13d-3 promulgated under the
Exchange Act (as defined herein)) of Company Common Stock decreases to less than the Minimum Ownership Threshold, the right of Investor pursuant to this Section 1(a)(ii) to participate in the recommendation of an Investor Replacement Director
to nominate a substitute Investor Director prior to the 2019 Annual Meeting or fill the vacancy caused by the resignation or removal of the Investor Director or any Investor Replacement Director following the 2019 Annual Meeting shall automatically
terminate. Prior to the nomination or appointment of any Investor Replacement Director to the Board, (i) Investor will deliver to the Company an irrevocable resignation letter pursuant to which the Investor Replacement Director shall offer to
resign from the Board and all applicable committees and subcommittees thereof if, at any time after the 2019 Annual Meeting, Investor’s aggregate beneficial ownership (as determined under Rule 13d-3
promulgated under the Exchange Act), of Company Common Stock decreases to less than the Minimum Ownership Threshold, such irrevocable resignation not to be effective until the Board shall have accepted such resignation, which acceptance shall be
made within the sole and absolute discretion of the Board, and (ii) the Investor Replacement Director will submit to the Board the information, documentation and acknowledgements set forth in Section 1(b)(iv) of this Agreement. 

(iii)    The Company shall include the Investor Director on its slate of directors to be elected to the
Board at the 2019 Annual Meeting and at each meeting of stockholders subsequent to the 2019 Annual Meeting held for the purposes of electing directors during the Standstill Period at which the Investor Director’s term expires and shall use its
reasonable best efforts (which shall include the solicitation of proxies) to cause the election of the Investor Director at the 2019 Annual Meeting (it being understood that such efforts shall not be less than the efforts used by the Company to
cause the election of any other non-management director nominee nominated by the Company) and at each subsequent meeting of stockholders held for the purposes of electing directors during the Standstill Period
at which the Investor Director’s term expires. Notwithstanding this Section 1(a)(iii), the Company may determine not to include the Investor Director on its slate of directors to be elected to the Company Board at any annual meeting of the
Company’s stockholders at which the Investor Director’s term expires, in which case, this Agreement shall terminate upon written notice (which notice must be delivered no later than thirty (30) days prior to the deadline for the
submission of the nomination notice for such annual meeting of stockholders) to Investor of such determination not to nominate the Investor Director for election to the Board. 

(b)    Additional Agreements. 

(i)    Investor agrees that it will cause its controlled Affiliates and Associates, including but not
limited to Cevian Capital AB (Stockholm), Cevian Capital AG (Zürich) and Cevian Capital LLP (UK), to comply with the terms of this Agreement and shall be responsible for any breach of this Agreement by any such controlled Affiliate or
Associate. As used in this Agreement, the terms “Affiliate” and “Associate” shall have 

 
the respective meanings set forth in Rule 12b-2 promulgated by the SEC under the Securities Exchange Act of 1934, as amended, or the rules or regulations
promulgated thereunder (the “Exchange Act”) and shall include all persons or entities that at any time during the term of this Agreement become Affiliates or Associates of any person or entity referred to in this Agreement. 

(ii)    In connection with any annual or special meeting of the stockholders of the Company (and any
adjournments or postponements thereof) held during the Standstill Period (as defined herein), Investor will cause to be present for quorum purposes and vote or cause to be voted all shares of Company Common Stock beneficially owned (as determined
under Rule 13d-3 promulgated under the Exchange Act) by Investor of any of its Affiliates, and entitled to vote as of the record date for any such meeting, (A) in favor of the slate of directors
recommended by the Board and (B) otherwise in accordance with the Board’s recommendation on any proposal not related to an Extraordinary Transaction (as defined herein, with the reference “at least fifteen percent (15%)” replaced
with “any” in such definition for the purposes of this clause); provided that, if Institutional Shareholder Services Inc. recommends a vote different than the Board’s recommendation on a proposal other than the election of
directors, then Investor can vote in its sole discretion as it wishes on such proposal. 

(iii)    Concurrently with the execution of this Agreement, Investor has delivered to the Company an
irrevocable resignation letter pursuant to which the Investor Director has agreed to offer her resignation from the Board and all applicable committees and subcommittees thereof if, at any time after the 2019 Annual Meeting, Investor’s
aggregate beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act), of Company Common Stock decreases to less than the Minimum Ownership Threshold. The Investor Director’s
irrevocable resignation shall not be effective until the Board shall have accepted such resignation, which acceptance shall be made within the sole and absolute discretion of the Board. 

(iv)    Prior to the date of this Agreement, the Investor Director has submitted to the Company (A) a
fully completed copy of the Company’s director & officer questionnaire and other reasonable and customary director onboarding documentation required by the Company of non-management directors in
connection with the appointment or election of new Board members, (B) the information required pursuant to Section 6 of Article II of the Company’s Third Restated By-Laws (the “By-Laws”), (C) a written acknowledgment that the Investor Director agrees to be bound by all current policies, codes and guidelines applicable to directors of the Company, including, without limitation, the
Company’s trading policy, code of conduct and ethics for directors, corporate governance guidelines, and related person transaction policy, and (D) a written acknowledgment that the Investor Director (or Investor Replacement Director, as
applicable) agrees to maintain the confidentiality of Confidential Information (as hereinafter defined) and use Confidential Information only for the purpose of her service as a director of the Company and in accordance with her fiduciary duties as
a director of the Company under applicable law; provided that Investor Director may share Confidential Information with Investor to the extent permitted by United States and Swedish securities laws and the listing standards of any exchange on
which the securities of the Company are listed. 
 (v)    Investor agrees that the Board or any committee
or subcommittees thereof, in the exercise of its fiduciary duties, may recuse the Investor Director from the portion of any Board or committee or subcommittee meeting at which the Board or any such committee or subcommittee is evaluating and/or
taking action with respect to (i) Investor’s ownership of Company Common Stock, (ii) the exercise of any of the Company’s rights or enforcement of any of the obligations under this Agreement, (iii) any action taken in
response to actions taken by Investor or its Affiliates with respect to the Company or (iv) any transaction with Investor or its Affiliates. 

 2.    Standstill Provisions. 

(a)    Investor agrees that from the date the Investor Director is elected or appointed to the Board until thirty
(30) days following the time that Investor Director no longer serves as a director on the Board (the “Standstill Period”), neither it nor any of its Affiliates or Associates under its control or direction will, and it will
cause each of its Affiliates and Associates under its control not to, directly or indirectly, in any manner, alone or in concert with others: 

(i)    acquire, or offer, seek or agree to acquire, by purchase or otherwise, or direct others in the
acquisition of, any securities issued by the Company or securities convertible into or exchangeable for Company Common Stock (or any rights decoupled from the underlying securities) or assets of the Company, or rights or options to acquire any
securities issued by the Company or securities convertible into or exchangeable for Company Common Stock (or rights decoupled from the underlying securities) or assets of the Company, or engage in any swap or hedging transactions or other derivative
agreements of any nature with respect to securities issued by the Company or securities convertible into or exchangeable for Company Common Stock (or rights decoupled from the underlying securities) that are settled by delivery of Company Common
Stock or assets of the Company, in case of each of the foregoing, only if such action would result in Investor, together with its Affiliates and Associates, having an aggregate beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act but treating all shares underlying options or synthetic derivatives as outstanding whether or not then exercisable) of nineteen and nine-tenths percent (19.9%) or more of the
then-outstanding Company Common Stock immediately following the consummation of such transaction; provided that nothing herein will require Company Common Stock to be sold to the extent that Investor exceeds the ownership limit under this
clause (i) as the result of a share repurchase or similar Company action that reduces the number of outstanding shares of Company Common Stock; 

(ii)    engage in any short sale or any purchase, sale or grant of any option, warrant, convertible
security, stock appreciation right, or other similar right (including any put or call option or “swap” transaction with respect to any security (other than a broad-based market basket or index)) or enter into a derivative or other
agreement, arrangement or understanding that hedges or transfers, in whole or in part any securities that includes, relates to or derives any significant part of its value from a decline in the market price or value of any securities of the Company
(or any rights decoupled from the underlying securities); 
 (iii)    initiate, effect or participate in
any way in, or seek to offer or propose to effect, cause or participate in any way in, any tender or exchange offer, merger, consolidation, acquisition, sale of all or substantially all assets or sale, spinoff, splitoff or other similar separation
of one or more business units, scheme of arrangement, plan of arrangement, business combination transaction, extraordinary dividend, significant stock repurchase, recapitalization, restructuring, reorganization, liquidation, dissolution or issuance
of at least fifteen percent (15%) of the Company’s then-outstanding equity or equity equivalent securities (including in a PIPE, convertible note, convertible preferred security or similar structure) or other extraordinary transaction involving
the Company or any of its subsidiaries or joint ventures or any of their respective securities or a material amount of any of their respective assets or businesses (each, an “Extraordinary Transaction”); provided that nothing
in this Section 2(a) will prohibit the Investor Director from privately (without any public disclosure) advocating for such actions with the Board or prohibit Investor from privately (without any public disclosure) engaging in discussions with
its advisors and its consultants regarding an Extraordinary Transaction or participating in such transaction or any other actions approved by the Board; provided further that this clause (a)(iii) shall not restrict: (x) the tender (or
failure to tender) by Investor or any of its Affiliates of any securities of the Company into any tender or exchange offer; (y) the vote 

 
for or against any Extraordinary Transaction by Investor or any of its Affiliates of any securities of the Company, or (z) the receipt of any consideration by Investor or any of its
Affiliates on the same basis as other stockholders of the Company in connection with an Extraordinary Transaction; 

(iv)    submit any proposal for consideration at, or bring any other business before, any annual or special
meeting of the stockholders of the Company (or any adjournments or postponements thereof); 

(v)    solicit, or knowingly encourage or in any way engage in any solicitation of, any proxies or consents
or become a “participant” in a “solicitation”, directly or indirectly, as such terms are defined in Regulation 14A under the Exchange Act, of proxies or consents (including, without limitation, any solicitation of consents that
seeks to call a special meeting of stockholders or by initiating, encouraging or participating in any “withhold” or similar campaign), in each case, with respect to securities of the Company or any securities convertible or exchangeable
into or exercisable for any such securities; 
 (vi)    with respect to Company Common Stock, make any
communication or announcement (other than in the ordinary course of business on a confidential basis to its investors) stating how its shares of Company Common Stock will be voted, or the reasons therefor or otherwise communicate pursuant to Rule 14a-1(l)(2)(iv) under the Exchange Act; 
 (vii)    knowingly make any
recommendations or knowingly seek to advise, encourage, support or influence any person with respect to the voting or disposition of any securities of the Company at any annual or special meeting of stockholders, except in accordance with
Section 1(b)(ii) of this Agreement, or seek to do so; 
 (viii)    form or join in a partnership,
limited partnership, syndicate or other group, including, without limitation, a group as defined under Section 13(d) of the Exchange Act, with respect to any Company Common Stock; provided, however, that nothing herein shall limit
the ability of an Affiliate of Investor to join the “group” following the execution of this Agreement, so long as any such Affiliate is bound by the terms and conditions of this Agreement; 

(ix)    deposit any Company Common Stock in any voting trust or subject any Company Common Stock to any
arrangement or agreement with respect to the voting of any Company Common Stock, other than any such voting trust, arrangement or agreement solely among the Affiliates or Associates of Investor and otherwise in accordance with this Agreement,
provided that any such Affiliate or Associate is bound by the terms and conditions of this Agreement; 

(x)    act alone or in concert with others to control or seek to control or make any public proposal or
requests with respect to controlling, changing or influencing the Board or management of the Company, including any plans or proposals relating to any change in the number, class or term of directors of the Company, the filling of any vacancies on
the Board or any representation on the Board, except as specifically contemplated in Section 1(a) of this Agreement; 

(xi)    seek or submit, or knowingly encourage any person or entity to seek or submit, nominations in
furtherance of a “contested solicitation” for the election or removal of directors of the Company or seek, knowingly encourage or take any other action with respect to the election or removal of any directors of the Company, except as
specifically contemplated in Section 1(a) of this Agreement; 
 (xii)    make any public disclosure,
communication, announcement or statement with respect to (A) any plan or proposal with respect to the Board, the Company, its management, policies or affairs, any of its securities or assets or any of its businesses of strategy (including with
respect to any Extraordinary Transaction) or (B) any plan or proposal that is inconsistent with the terms of this Agreement; 

 (xiii)    make a request for a list of the
Company’s stockholders or for any books and records of the Company; 
 (xiv)    make any public
request or submit any public proposal to amend or waive any term of this Agreement (including the provisions of this Section 2) or take any action that could reasonably lead to public disclosure of such a request or proposal by any Party; 

(xv)    commence, institute, solicit, encourage, support or join, as a party, any litigation, arbitration
or other proceeding (including a derivative action) against or involving the Company or any of its current or former directors or officers, including any action challenging the validity or enforceability of this Section 2 or this Agreement,
other than (A) litigation by Investor to enforce the provisions of this Agreement, (B) counterclaims with respect to any proceeding initiated by, or on behalf of, the Company or its Affiliates against Investor or its Affiliates or
Associates, (C) the exercise of statutory appraisal, dissenters or similar rights under the Delaware General Corporation Law; and (D) bringing bona fide commercial disputes that do not relate to the subject matter of this Agreement;
provided that the foregoing shall also not prevent Investor from responding to, or complying with, a validly issued legal process that Investor did not initiate, encourage, aid or abet; or 

(xvi)    other than as otherwise set forth in this Section 2(a), (A) enter into any negotiations,
discussions, agreements or understandings with others (whether written or oral) to take any action with respect to any of the foregoing, or (B) knowingly advise, facilitate, finance (through equity, debt or otherwise), assist, solicit,
encourage or seek to persuade any other person or entity to take any action inconsistent with any of the foregoing. 
 Notwithstanding the
foregoing, the restrictions in this Section 2(a) shall terminate automatically upon the earliest of (i) the fifth (5th) business day after written notice is delivered by Investor to the Company of a material breach of this Agreement by the
Company (including, without limitation, a failure to nominate or appoint the Investor Director or, as applicable, an Investor Replacement Director, in accordance with Section 1 of this Agreement or a breach of applicable non-disparagement obligations under Section 11 of this Agreement) if such breach has not been cured within such notice period, provided that Investor is not in material breach of this Agreement at the
time such notice is given, (ii) the announcement by the Company of a definitive agreement with respect to any Extraordinary Transaction that would result in the acquisition by any person or group of more than 50% of the then-outstanding shares
of Company Common Stock or (iii) the commencement of any tender or exchange offer (by a person other than Investor, its Affiliates or Associates) which, if consummated, would constitute an Extraordinary Transaction that would result in the
acquisition by any person or group of more than 50% of the then-outstanding shares of Company Common Stock, where the Company files a Schedule 14D-9 (or any amendment thereto), other than a “stop, look
and listen” communication by the Company pursuant to Rule 14d-9(f) promulgated under the Exchange Act, that does not recommend that the Company’s stockholders reject such tender or exchange offer.

 (b)    Subject to complying with its obligations under Sections 1(b)(iv), 2(a), 11 and 12 of this Agreement, Investor
may engage in any private discussions in the ordinary course of its business with third parties so long as such private communications would not be reasonably determined to trigger public disclosure obligations for any such party. 

(c)    The restrictions in this Section 2 shall not prevent Investor or any of its Affiliates from making any factual
statement as required by applicable legal process, subpoena, or legal requirement from any governmental authority with competent jurisdiction over the party from whom information is sought (so long as such request did not arise as a result of
discretionary acts by Investor or any of its Affiliates). 

 (d)    To the extent that the Investor Director is a principal or
employee of Investor, nothing in this Section 2 shall be deemed to limit the exercise in good faith by such Investor Director of her fiduciary duties solely in her capacity as a director of the Company. 

(e)    Nothing in this Section 2 shall be deemed to prohibit Investor from communicating privately with the
Company’s Chief Executive Officer and Chairman, General Counsel, Chief Financial Officer, directors and members of the Company’s investor relations team in accordance with Section 13 of this Agreement, so long as such private
communications would not be reasonably determined to trigger public disclosure obligations for any Party. 

(f)    Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall prevent Investor from
making public statements regarding any Extraordinary Transaction announced by or involving the Company, and nothing in this Agreement shall prevent the Company from responding to such statements, subject to the obligations of the Parties under
Section 11 of this Agreement; provided, however, that a criticism of such Extraordinary Transaction shall not be considered a breach of the obligations of the Parties under Section 11 of this Agreement. 

3.    Representations and Warranties of the Company. 

The Company represents and warrants to Investor that (a) it has the corporate power and authority to execute this Agreement and to bind it
thereto, (b) this Agreement has been duly and validly authorized, executed and delivered by it, constitutes a valid and binding obligation and agreement of it, and is enforceable against it in accordance with its terms, except as enforcement
thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles and (c) the execution, delivery
and performance of this Agreement by it does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to it, or (ii) result in any breach or violation of or constitute a default (or an
event which with notice or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation
of, any organizational document, agreement, contract, commitment, understanding or arrangement to which it is a party or by which it is bound. 

4.    Representations and Warranties of Investor. 

Investor represents and warrants to the Company that (a) the authorized signatory of Investor set forth on the signature page hereto has
the power and authority to execute this Agreement and any other documents or agreements to be entered into in connection with this Agreement and to bind Investor thereto, (b) this Agreement has been duly authorized, executed and delivered by
Investor, and is a valid and binding obligation of Investor, enforceable against Investor in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c) the execution of this Agreement, the consummation of any of the transactions contemplated hereby, and the fulfillment of the
terms hereof, in each case in accordance with the terms hereof, will not conflict with, or result in a breach or violation of the organizational documents of Investor as currently in effect, (d) the execution, delivery and performance of this
Agreement by Investor does not and will not violate or conflict with (i) any law, rule, regulation, order, judgment or decree applicable to Investor, or (ii) result in any breach or violation of or constitute a default (or an event which
with notice or lapse of time or both could constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any
organizational document, agreement, contract, commitment, understanding or arrangement to which Investor is a party or by which it is bound, (e) as of the date of this Agreement, 

 
Investor is deemed to beneficially own (as determined under Rule 13d-3 promulgated under the Exchange Act) in the aggregate 8,376,924 shares of Company
Common Stock, (f) as of the date hereof, Investor does not currently have, and does not currently have any right to acquire or any interest in any other securities of the Company (or any rights, options or other securities convertible into or
exercisable or exchangeable (whether or not convertible, exercisable or exchangeable immediately or only after the passage of time or the occurrence of a specified event) for such securities or any obligations measured by the price or value of any
securities of the Company or any of its Affiliates, including any swaps or other derivative arrangements designed to produce economic benefits and risks that correspond to the ownership of Company Common Stock, whether or not any of the foregoing
would give rise to beneficial ownership (as determined under Rule 13d-3 promulgated under the Exchange Act), and whether or not to be settled by delivery of Company Common Stock, payment of cash or by other
consideration, and without regard to any short position under any such contract or arrangement), and (g) Investor has not, directly or indirectly, compensated or agreed to, and will not, compensate the Investor Director for her respective
service as a director of the Company with any cash, securities (including any rights or options convertible into or exercisable for or exchangeable into securities or any profit sharing agreement or arrangement), or other form of compensation
directly or indirectly related to the Company or its respective securities, other than any performance-based compensation tied to Investor’s investments. 

5.    Termination. 

This Agreement shall remain in full force and effect until the earliest of: 

(a)     the expiration of the Standstill Period; or 

(b)    such other date established by mutual written agreement of the Parties hereto; 

provided, that such termination shall not relieve any Party or the Investor Director from its obligations under Section 12 of this Agreement,
which obligations shall survive in accordance with their terms. 
 6.    Specific Performance. 

Each of Investor, on the one hand, and the Company, on the other hand, acknowledge and agree that irreparable injury to the other Party hereto
would occur in the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately compensable by the remedies available at law
(including the payment of money damages). It is accordingly agreed that Investor, on the one hand, and the Company, on the other hand (the “Moving Party”), shall each be entitled to specific enforcement of, and injunctive relief to
prevent any violation of, the terms hereof, and the other Party hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law or in
equity. This Section 6 is not the exclusive remedy for any violation of this Agreement. 

7.    Severability. 

If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated. The Parties agree to use their commercially
reasonable best efforts to agree upon and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable by a court of competent jurisdiction. 

 8.    Notices. 

Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon confirmation of receipt, when sent by email (provided such confirmation is not automatically generated); or (iii) one (1)
business day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the Party to receive the same. The addresses and facsimile numbers for such communications shall be: 

 

			
	If to the Company:	  	Autoliv, Inc.
		  	Klarabergsviadukten 70, Section B7
		  	Box 70381, SE-107 24
		  	Stockholm, Sweden
		  	 Attention: Anthony Nellis, Executive Vice

President – Legal Affairs, General Counsel and Secretary

		  	Telephone: (248) 882-9517
		  	Email: anthony.nellis@autoliv.com
		
	With copies (which shall not constitute notice) to:	  	Alston & Bird LLP
		  	950 F Street NW
		  	Washington, DC 20004
		  	Attention: Dennis O. Garris
		  	                 David A. Brown
		  	Telephone: (202) 239-3452
		  	                   (202) 239-3463
		  	Email: Dennis.Garris@alston.com
		  	            Dave.Brown@alston.com
		
	If to Investor:	  	Cevian Capital II GP Limited
		  	11-15 Seaton Place
		  	St. Helier, Jersey JE4 0QH
		  	Channel Islands
		  	Attention: Denzil Boschat
		  	Telephone: +44 1534 828 513
		  	Email: Denzil.Boschat@ceviancapital.com
		
	With a copy (which shall not constitute notice) to:	  	Schulte Roth & Zabel LLP
919 Third Avenue
		  	New York, NY 10022
		  	Attention: Eleazer Klein
		  	Telephone: (212) 756-2376
		  	Email: Eleazer.Klein@srz.com

 9.    Applicable Law. 

This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without reference to the
conflict of laws principles thereof. Each of the Parties hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any
judgment in respect of this Agreement and the rights and obligations arising hereunder brought by the other Party hereto or its successors or assigns, shall be brought and determined exclusively in the federal or state courts located in Wilmington,
Delaware. Each of the Parties hereto hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees
that it will not bring any action relating to this Agreement in any court other than the aforesaid courts. Each of the Parties hereto hereby irrevocably waives, and agrees not to assert in any action or proceeding with respect to this Agreement,
(i) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason, (ii) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process
commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (iii) to the fullest extent permitted by applicable legal
requirements, any claim that (A) the suit, action or proceeding in such court is brought in an inconvenient forum, (B) the venue of such suit, action or proceeding is improper or (C) this Agreement, or the subject matter hereof, may
not be enforced in or by such courts. 

 10.    Counterparts. 

This Agreement may be executed in two or more counterparts, each of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each of the Parties and delivered to the other Parties (including by means of electronic delivery or facsimile). 

11.    Mutual Non-Disparagement. 

Subject to applicable law, the Company, on the one hand, and Investor, on the other hand, covenants and agrees that, during the Standstill
Period or if earlier, until such time as the other or any of its agents, subsidiaries, affiliates, successors, assigns, officers, key employees or directors shall have breached this Section 11, neither it nor any of its respective agents,
subsidiaries, affiliates, successors, assigns, principals, partners, members, general partners, officers, key employees or directors, shall in any way publicly criticize, disparage, call into disrepute, or otherwise defame the other or such
other’s subsidiaries, affiliates, successors, assigns, officers (including any current officer of the other or the other’s subsidiaries who no longer serves in such capacity following the execution of this Agreement), directors (including
any current director of the other or the other’s subsidiaries who no longer serves in such capacity following the execution of this Agreement), employees, stockholders (solely in their capacity as stockholders of the applicable Party), agents,
attorneys or representatives, or any of their businesses, products or services, in any manner that would reasonably be expected to damage the business or reputation of such other , their businesses, products or services or their subsidiaries,
affiliates, successors, assigns, officers (or former officers), directors (or former directors), employees, stockholders (solely in their capacity as stockholders of the applicable Party), agents, attorneys or representatives. This Section 11
shall not limit the power of any director the Company to make such statements as required by applicable law or make comments that are consistent with the provisions hereof nor shall it apply to any private communications between Investor and its
Affiliates and its and their respective principals, directors, members, general partners, officers and key employees, on the one hand, and any Contact Personnel (as defined herein) of the Company, on the other hand, to the extent that it would not
be reasonably expected that such communication would trigger public disclosure obligations for any such party. 

12.    Confidentiality. 

(a)    Investor hereby agrees that if it receives any non-public information
entrusted to or obtained by Investor Director by reason of her position as a director of the Company (“Confidential Information”) or any other material non-public information regarding any
other person or entity, then Investor will (i) maintain the strict confidentiality of such Confidential Information or material non-public information, and (ii) abstain from trading in securities of
the Company in violation of applicable law while in possession of any such Confidential Information or material non-public information. Investor will abstain from trading in any securities of the Company
(including any swap or hedging transactions or other derivative agreements of any nature with respect to securities issued by the Company or securities convertible into or exchangeable for Company Common Stock (or rights decoupled from the
underlying securities)) for the time periods during which the Investor Director is prohibited from such trading pursuant to the Company’s trading policy. Subject to compliance with applicable laws, Investor shall in any event be free to trade
or engage in the foregoing transactions (i) during any such “open window” periods when the directors of the Company generally are permitted to do so and (ii) from and any time after the opening of the first open window period
following the cessation of the Investor Director’s service as a member of the Board as contemplated herein. The Company will notify Investor in advance when such open window period begins. 

(b)    Notwithstanding anything in this Agreement to the contrary, in the event that Investor or any of its Affiliates are
required in connection with a legal, judiciary, regulatory or administrative investigation or proceeding, by interrogatories, subpoena, civil investigative demand or similar legally mandatory process (excluding any such requirement arising out of
any action or proceeding initiated by Investor or any of its Affiliates, including for the avoidance of doubt any requirement to make a filing 

 
with the SEC or under any securities laws or regulations, or any requirement arising out of a breach of this Agreement by Investor or its Affiliates) (each, a “Legal
Requirement”), to disclose Confidential Information, it is agreed that Investor or such Affiliate, as applicable, will, to the extent legally permissible, provide the Company with prompt (and in any case, prior to the disclosure) written
notice of such event so that the Company may seek a protective order or other appropriate remedy, at the sole expense of the Company, or waive compliance with the applicable provisions of this Agreement and, if applicable, the Company’s code of
conduct and ethics for directors by Investor or such Affiliate. In the event that (x) such protective order or other remedy is not obtained and disclosure of Confidential Information is therefore required pursuant to such Legal Requirement or
(y) the Company consents in writing to having the Confidential Information produced or disclosed pursuant to such Legal Requirement, then Investor or its Affiliate, as the case may be, (i) may, without liability hereunder, furnish that
portion (and only that portion) of the Confidential Information that Investor or such Affiliate’s outside legal counsel advises is legally required to be disclosed and (ii) will use reasonable efforts, at the Company’s sole expense,
to obtain reasonable assurance that confidential treatment is accorded to any Confidential Information so furnished. In no event will Investor or its Affiliates, as applicable, oppose any action by the Company to obtain a protective order or other
relief to prevent the disclosure of the Confidential Information or to obtain reliable assurance that confidential treatment will be afforded to the Confidential Information. 

(c)    Any confidentiality obligations under this Section 12 or Section 1(b)(iv) of this Agreement shall expire
eighteen (18) months after the date on which the Investor Director ceases to serve as a director of the Comapny; provided, that Investor shall maintain in accordance with the confidentiality obligations set forth herein any Confidential
Information constituting trade secrets for such longer time as such information constitutes a trade secret of the Company as defined under 18 U.S.C. § 1839(3); and provided, further, that the obligations in this Section 12(c)
are not intended to be, and shall not be interpreted as, a contractual restriction on any trading activities of Investor or its Affiliates taken in the sole judgment of Investor or its Affiliates in accordance with applicable law. 

13.    Communications with Management of the Company. 

(a) All communications regarding the Company between the members of the Company’s Board of Directors and Company’s management team,
on the one hand, and the representatives of Investor and its Affiliates, on the other hand, will be coordinated through the Company’s Chairman, Chief Executive Officer Chief Financial Officer, General Counsel and/or representatives of the
Company’s investor relations team (“Contact Personnel”), and (ii) Investor agrees that, except as otherwise consented to in advance in writing by the Company or as permitted by this Agreement, neither Investor nor its
Affiliates will initiate or maintain contact with any officer, director or employee of the Company. 
 (b) Nothing in this Section 13
will apply to (i) the Investor Director when acting in her capacity as a director of the Company or (ii) communications by Investor in the ordinary course of business at investor or industry meetings or conferences, which communications
shall be subject to compliance with the other provisions of this Agreement. 
 (c) Nothing in this Section 13 constitutes a commitment
on the part of the Company or any of its representatives to make any disclosures to Investor or any of its Affiliates. 

14.    Public Announcements. 

The Company shall announce this Agreement by means of a press release, the content of which shall be mutually agreed-upon by both parties
hereto (the “Press Release”). Neither the Company nor Investor shall make or cause to be made any public announcement or statement with respect to the subject of this Agreement that is contrary to the statements made in the Press
Release, except as required by law or the rules of any stock exchange or with the prior written consent of the other Party. The Company acknowledges that Investor may file this Agreement as an exhibit to its Schedule 13D. The Company shall be given
a reasonable opportunity to review and comment on any Schedule 13D filing made by Investor with respect to this Agreement prior to the filing with the SEC, and Investor shall give reasonable consideration in good faith to any reasonable comments of
the Company. Investor 

 
acknowledges and agrees that the Company may file this Agreement and file or furnish the Press Release with the SEC as exhibits to a Current Report on Form
8-K and other filings with the SEC. Investor shall be given a reasonable opportunity to review and comment on the Form 8-K made by the Company with respect to this
Agreement prior to the filing with the SEC, and the Company shall give reasonable consideration in good faith to any reasonable comments of Investor. 

15.    Entire Agreement; Amendment and Waiver; Successors and Assigns; Third Party Beneficiaries; Affiliates and
Associates. 
 This Agreement contains the entire understanding of the Parties hereto with respect to its subject matter. There are no
restrictions, agreements, promises, representations, warranties, covenants or undertakings between the Parties other than those expressly set forth herein. No modifications of this Agreement can be made except in writing signed by an authorized
representative of each of the Parties, provided, however, any modification of this Agreement that does not implicate all Parties may be entered into by the Parties so implicated by such modification, so long as such modification does
not adversely affect the Party not entering into such modification. No failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial
exercise of such right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by
law. The terms and conditions of this Agreement shall be binding upon, inure to the benefit of, and be enforceable by the Parties hereto and their respective successors, heirs, executors, legal representatives, and permitted assigns. No Party shall
assign this Agreement or any rights or obligations hereunder without, with respect to Investor, the prior written consent of the Company, and with respect to the Company, the prior written consent of Investor. This Agreement is solely for the
benefit of the Parties hereto and is not enforceable by any other persons or entities. Notwithstanding anything contained in the definitions of “Affiliate” or “Associates” to the contrary, for purposes of this Agreement, the
covenants applicable to Investor as set forth in this Agreement shall only require Investor to cause its portfolio companies to take or refrain from taking action to the extent Investor has a contractual, legal or other right or ability to cause
such portfolio company to take or refrain from taking such action (provided, that it shall also constitute a breach of any such covenant for Investor to request, instruct or direct any of its portfolio companies to take any action or fail to
take any action which action or failure to act would, if taken by Investor, constitute a breach of this Agreement). 
 [The remainder of
this page intentionally left blank] 

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly
authorized signatories of the Parties as of the date hereof. 
  

			
	AUTOLIV, INC.
		
	By:	 	 /s/ Mikael Bratt

	Name:	 	Mikael Bratt
	Title:	 	President and Chief Executive Officer
	
	CEVIAN CAPITAL II GP LIMITED
		
	By:	 	 /s/ Denzil Boschat

	Name:	 	Denzil Boschat
	Title:	 	Authorized Signatory

 [Signature Page to Cooperation Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]